Baker Machhadieh, MD
Endocrinology, Diabetes & Metabolism · Hamilton, OHNPI 1518167295
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $273,425 of the $303,696 with a category attached, or 90.0%. Lilly USA, LLC accounts for 99.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $65,729 and has fallen 53.0% since, to $30,874 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $628.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$303K
- Novo Nordisk$461
- Sanofi-aventis U.S. LLC$121
- Insulet Corporation$98
- Amgen$85
- AstraZeneca$78
- plus $54 from 1 others
What the payments were for
- Consulting fees$6,9062%
- Speaking & faculty fees$273,42590%
- Travel & lodging$18,2646%
- Food & beverage$5,0412%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 471 | $302,800 |
| Novo Nordisk | 7 | $461 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Insulet Corporation | 1 | $98 |
| Amgen | 1 | $85 |
| AstraZeneca | 1 | $78 |
| Medtronic | 1 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$169,863
- TRULICITY$97,217
- HUMULIN$16,002
- SOLIQUA 100/33$121
- Wegovy$121
How this compares
$303,696 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 624 | $715,038 |
| JardianceEmpagliflozin | 618 | $538,492 |
| OzempicSemaglutide | 209 | $324,957 |
| MounjaroTirzepatide | 243 | $307,639 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 120 | $172,548 |
| JanuviaSitagliptin Phosphate | 119 | $100,121 |
| Humalog Kwikpen U-200Insulin Lispro | 49 | $99,599 |
| FarxigaDapagliflozin Propanediol | 106 | $91,305 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 95 | $56,659 |
| TradjentaLinagliptin | 83 | $54,647 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $50,147 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $44,918 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 285 | $38,719 |
| Cinacalcet Hcl | 27 | $37,696 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $27,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi, Insulin Lispro | $302,800 | $1,048,3231,003 claims |
| Novo NordiskOzempic, Novolog | $461 | $343,193253 claims |
| AstraZenecaFarxiga | $78 | $91,305106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Hamilton
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
- Shawn PeavieCincinnati$201K
- Amanda DenneyCincinnati$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.